Abstract
Objective:
The present study assessed the feasibility of a definitive placebo-controlled trial for evaluating individualized homeopathy (IH) in stage I hypertension (HTN).
Design:
Double-blind, randomized (IH: 34, placebo: 34), placebo-controlled, parallel arms, pilot trial.
Settings/Location:
National Institute of Homoeopathy, India.
Subjects:
Patients suffering from stage I HTN.
Interventions:
IH and identical-looking placebo.
Outcome measures:
Feasibility issues, blood pressure (BP) and Measure Yourself Medical Outcome Profile-2 (MYMOP-2) were assessed for 6 months.
Results:
The recruitment and retention rates were 44.4% and 85.3%, respectively. Group differences were seemingly higher in the IH group than in the placebo group.
Conclusions:
Despite challenges in recruitment, an adequately powered efficacy trial appears feasible in the future.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
